Riskpilot← Back to searchSign inGet full accessINNOVEST AS
ASActiveOrg 983636713Nygårdsgaten 5, 5015 BergenResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employeesinnovest.no
Revenue 2024
NOK 0
EBITDA margin
—
+52% vs 2023
Equity ratio
-70.1%
Financial strength
Net profit 2024
NOK 288K
+125% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -827K | +52% |
| Net profit | NOK 288K | +125% |
| Total assets | NOK 17M | +7% |
| Equity | NOK -11,9M | +2% |
| Employees | 0 | — |
Legal name
INNOVEST AS
Org number
983636713
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5. september 2001
Share capital
NOK 14 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Eie aksjer i selskap som driver med forskning og innovasjon innen helse og medisin.
Address
Nygårdsgaten 5, 5015 Bergen
Website
innovest.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65 403 | 50 425 | 5 845 | 9 255 | 3 631 | 1 732 | 571 | 3 584 | 778 | 207 | 7 | 200 | 0 |
| Staff expenses | −5 345 | −6 031 | −6 084 | −2 815 | −711 | −315 | −224 | −243 | −347 | −331 | −274 | −160 | −160 |
| EBITDA | −5 970 | −7 010 | −12 234 | −1 089 | −1 559 | −2 357 | −5 427 | 105 | −2 167 | −1 375 | −2 434 | −1 732 | −827 |
| Depreciation & amort. | −139 | −569 | −607 | −460 | −93 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 109 | −7 580 | −12 841 | −1 549 | −1 652 | −2 357 | −5 427 | 105 | −2 167 | −1 375 | −2 434 | −1 732 | −827 |
| Net financials | 3 824 | 8 126 | 3 634 | 1 368 | 1 811 | 121 | 336 | 364 | 402 | 432 | 262 | 561 | 1 115 |
| Profit before tax | −2 285 | 547 | −9 207 | −181 | 159 | −2 236 | −5 091 | 469 | −1 764 | −944 | −2 172 | −1 171 | 288 |
| Tax | −1 289 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −996 | 547 | −9 207 | −181 | 159 | −2 236 | −5 091 | 469 | −1 764 | −944 | −2 172 | −1 171 | 288 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 142 261 | 116 695 | 53 630 | 63 118 | 49 616 | 44 657 | 23 937 | 19 398 | 17 003 | 15 662 | 16 231 | 15 982 | 17 034 |
| Equity | −1 049 | 3 526 | −11 293 | 526 | 685 | −1 551 | −6 642 | −6 173 | −7 938 | −8 881 | −11 053 | −12 224 | −11 936 |
| Long-term debt | 0 | 0 | 0 | 3 000 | 3 000 | 3 000 | 3 000 | 0 | 0 | 0 | 0 | 6 000 | 6 842 |
| Short-term debt | 133 934 | 113 169 | 64 923 | 59 592 | 45 931 | 43 208 | 27 579 | 25 571 | 24 941 | 24 543 | 27 284 | 22 206 | 22 128 |
| Total debt | 133 934 | 113 169 | 64 923 | 62 592 | 48 931 | 46 208 | 30 579 | 25 571 | 24 941 | 24 543 | 27 284 | 28 206 | 28 970 |
EBITDA margin
-82712900.0%
This company
15.8%
Market median
-523499467% vs market
20122024
Equity ratio
-70.1%
This company
38.2%
Market median
-284% vs market
20122024
Return on equity
28763500.0%
This company
18.4%
Market median
+156323270% vs market
20122024
Net profit margin
28763500.0%
This company
8.1%
Market median
+355104838% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
2.43×
This company
0.62×
Market median
-292% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KI Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Stiftelsen Universitetsforskning Bergen | Company | 50.0% | 50.0% | 2024 |
Helse Bergen Hf | Company | 50.0% | 50.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Stiftelsen Universitetsforskning Bergen
INNOVEST AS Board members of INNOVEST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjell Inge Arnevig | Chief Executive Officer | 0 companies |
| Trond Søreide | Chairman | 0 companies |
| Astrid Louise Grasdal | Board of Directors | 0 companies |
| Kristin Pundsnes | Board of Directors | 0 companies |
| Astrid Louise Hanssen Wang | Board of Directors | 0 companies |
| Egil Hermann Sjursen | Board of Directors | 0 companies |